NCI-MATCH Press Center

The materials posted in this section are a collection of press releases, announcements, news stories, and blogs about the NCI-MATCH trial. For media inquiries, send an email or call 215.789.3631.

Looking for a publication? Search and sort this NCI-MATCH Publications List.

June 15, 2023

Nature Medicine publishes key lessons from NCI-MATCH to guide future precision medicine trials. Media Advisory

May 8, 2023

NCI-MATCH named among five innovative oncology therapies changing the game. MDLinx

October 26, 2022

NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib in Arm Z1K. Press Release

August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval: Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600Emutation. Blog Post

June 22, 2022

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH. OncLive

June 1, 2022

Precision medicine clinical trials: A conversation between Peter O’Dwyer and Lale Kostakoglu. The Journal of Nuclear Medicine

April 15, 2022

NCI-MATCH: The Blueprint for Future Precision Medicine Trials. In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee of the Developmental Therapeutics Committee is offering expertise moving forward. Blog Post

April 11, 2022

As NCI-MATCH winds down, the cancer research community takes stock of lessons learned. Precision Oncology News/GenomeWeb

March 17, 2022

NCI-MATCH umbrella trial adds arm for LAG-3 expressing, mismatch repair deficient cancers. Precision Oncology News/GenomeWeb

March 16, 2022

ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations. Press Release

July 14, 2021

Matchmakers: How Basket Trials Match Patients With Drugs Based on Their Tumors. Cure Today

June 24, 2021

For patients with advanced or rare cancers, NCI-MATCH may offer a treatment option. Blog Post

Advocacy and the NCI’s National Clinical Trials Network Blog Post

May 7, 2021

NCI-MATCH has 12 open arms awaiting patients with advanced or rare cancers, and is expanding with the opening of a new treatment arm. Blog Post

April 27, 2021

The search for patients intensifies with the opening of a new NCI-MATCH treatment arm. Blog Post

April 26, 2021

A new study arm opens in NCI-MATCH, expanding patients’ potential to qualify for this precision medicine cancer clinical trial when they may not have other options. Press Release

October 19, 2020

A genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks. Blog Post

October 16, 2020

Data from the NCI-MATCH precision medicine trial established a new benchmark for next-generation sequencing in clinical trials. The Cancer Letter

October 14, 2020

NCI-MATCH data shows the value of platform trials for patients with rare genomically driven cancers. Interview with lead investigator Keith T. Flaherty, MD. Precision Oncology News/GenomeWeb

October 13, 2020

NCI-MATCH precision medicine cancer trial makes a major contribution to tumor gene testing for cancer treatment selection. Journal of Clinical Oncology publishes molecular analysis of 6000 NCI-MATCH patients. Press Release

August 13, 2020

In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report on Arm H. The combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAF V600>-mutated tumors outside of currently approved indications. OncLive

February 20, 2020

The results of Arm Z1D in the NCI-MATCH trial continue to attract media attention. Nilofer Azad, MD (Johns Hopkins) talks about the activity of nivolumab in MMR-deficient cancers in a feature article. MedPage Today/ASCO Reading Room

January 13, 2020

A series of changes were recently incorporated in Addendum #24 of the NCI-MATCH trial. Blog Post

January 7, 2020

Komal Jhaveri, MD, FACP (Memorial Sloan Kettering) is the primary author of the publication of NCI-MATCH Arm Q results, published in the Annals of Oncology. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors. Press Release

December 19, 2019

The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH. “The confirmed overall response rate for nivolumab in tumors with DNA mismatch repair deficiencies was 36%–or 15 of 42 patients with cancers other than colon,” says Nilofer Azad, MD (Johns Hopkins University). Press Release

June 3, 2019

Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations. “Arm H met its primary endpoint with an overall objective response rate of 33 percent,” said lead researcher April K. S. Salama, MD (Duke University). Press Release

November 12, 2018

NCI-MATCH precision medicine cancer trial enrolling 7-8 new patients weekly. Findings from Arm Y are to be presented at an international meeting. Press Release

June 4, 2018

NCI-MATCH (Molecular Analysis for Therapy Choice), the largest precision medicine trial of its kind, has achieved a milestone with the release of results of several treatment arms of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients with certain gene abnormalities. Press Release

May 30, 2018

NCI-MATCH (EAY131) achieves a milestone with the release of patient outcomes results from Arms I, Q, and W at the American Society of Clinical Oncology (ASCO) 2018 annual meeting. Press Release

July 7, 2017

James Doroshow discusses how NCI-MATCH tests the ability to integrate next-generation sequencing. The Cancer Letter

July 7, 2017

NCI-MATCH keeps enrolling. Targeted mutations are proving to be less common than estimated. The Cancer Letter

June 7, 2017

As the NCI-MATCH precision medicine cancer trial reaches its 6,000-patient tumor sequencing goal two years early, the trial continues with a new strategy to complete enrollment by casting a wider net for patients. Press Release

September 26, 2016

ECOG-ACRIN opens the quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ today. COMET is an ancillary study to the NCI-MATCH (EAY131) trial, already underway. Press Release

August 16, 2016

The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ to the NCI-MATCH (EAY131) trial, already underway. Press Release

May 26, 2016

The phase 2 precision medicine cancer trial, Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) is set to resume gene testing of patients on May 31, 2016, at 12:00 Noon Eastern Time. Press Release

September 4, 2015

The NCI-MATCH trial opens. The Cancer Letter

August 17, 2015

ECOG-ACRIN opens the phase 2 precision medicine cancer trial, National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131), the largest, most scientifically rigorous precision medicine trial in cancer to date, to cancer centers and community hospitals nationwide. Press Release

June 5, 2015

NCI-MATCH to bring in public, and private funds, giving NCI a new urgent scientific agenda. The Cancer Letter

June 5, 2015

Jim Doroshow on how NCI-MATCH is an example of what smart public-private partnerships can do. The Cancer Letter

June 1, 2015

National Cancer Institute and ECOG-ACRIN announce the NCI-MATCH / EAY131 trial, a multi-arm phase 2 precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancer type. Press Release

ECOG-ACRIN Cancer Research Group